Product Name :
ATM Inhibitor-1
Description:
ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0.73 μM). ATM Inhibitor-1 exhibits anti-tumor activity.
CAS:
2135639-94-8
Molecular Weight:
492.61
Formula:
C27H36N6O3
Chemical Name:
6-{6-[3-(dimethylamino)propoxy]pyridin-3-yl}-N-methyl-4-{[(1S)-1-(oxan-4-yl)ethyl]amino}cinnoline-3-carboxamide
Smiles :
C[C@H](NC1=C(N=NC2=CC=C(C=C21)C1=CN=C(C=C1)OCCCN(C)C)C(=O)NC)C1CCOCC1
InChiKey:
SJOFSBIUJPEXTG-SFHVURJKSA-N
InChi :
InChI=1S/C27H36N6O3/c1-18(19-10-14-35-15-11-19)30-25-22-16-20(6-8-23(22)31-32-26(25)27(34)28-2)21-7-9-24(29-17-21)36-13-5-12-33(3)4/h6-9,16-19H,5,10-15H2,1-4H3,(H,28,34)(H,30,31)/t18-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0.73 μM).{{Fezolinetant} web|{Fezolinetant} GPCR/G Protein|{Fezolinetant} Technical Information|{Fezolinetant} In Vivo|{Fezolinetant} custom synthesis|{Fezolinetant} Cancer} ATM Inhibitor-1 exhibits anti-tumor activity.|Product information|CAS Number: 2135639-94-8|Molecular Weight: 492.61|Formula: C27H36N6O3|Chemical Name: 6-{6-[3-(dimethylamino)propoxy]pyridin-3-yl}-N-methyl-4-{[(1S)-1-(oxan-4-yl)ethyl]amino}cinnoline-3-carboxamide|Smiles: C[C@H](NC1=C(N=NC2=CC=C(C=C21)C1=CN=C(C=C1)OCCCN(C)C)C(=O)NC)C1CCOCC1|InChiKey: SJOFSBIUJPEXTG-SFHVURJKSA-N|InChi: InChI=1S/C27H36N6O3/c1-18(19-10-14-35-15-11-19)30-25-22-16-20(6-8-23(22)31-32-26(25)27(34)28-2)21-7-9-24(29-17-21)36-13-5-12-33(3)4/h6-9,16-19H,5,10-15H2,1-4H3,(H,28,34)(H,30,31)/t18-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Fedratinib} medchemexpress|{Fedratinib} JAK/STAT Signaling|{Fedratinib} Biological Activity|{Fedratinib} In Vivo|{Fedratinib} manufacturer|{Fedratinib} Epigenetics} |Shelf Life: ≥12 months if stored properly.PMID:33356922 |Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|ATM Inhibitor-1 (Compound 21) is a highly potent, selective and orally active ATM Inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0.73 μM). In cellular assays, ATM Inhibitor-1 exhibits IC50s of 2.8 nM, >30 μM and >19 μM for ATM, ATR/PI3Kα and PI3Kβ/mTOR, respectively.|In Vivo:|ATM Inhibitor-1 (Compound 21; 50 mg/kg p.o. once daily for 3 days every week starting 24 h post-irinotecan dosing, 21 days) in combination with 50 mg/kg irinotecan significantly reduces tumor growth in SW620 mice model.|Products are for research use only. Not for human use.|
